Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study

BACKGROUND: Recent vasodilating drugs have improved prognosis of Pulmonary arterial hypertension (PAH). Some reports describe the merits of combination therapies for PAH, and this study evaluated the efficacy and safety of phosphodiesterase type 5 inhibitors (PDE5i) combination therapy, using silden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pulm Med
Main Authors: Kimura, Mai, Tamura, Yuichi, Takei, Makoto, Yamamoto, Tsunehisa, Ono, Tomohiko, Fujita, Jun, Kataoka, Masaharu, Kuwana, Masataka, Satoh, Toru, Fukuda, Keiichi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4436029/
https://ncbi.nlm.nih.gov/pubmed/25971443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-015-0037-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados